Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting

Completed · Not applicable

Conditions studied: Pharmacogenetics

In brief

This study aims to compare patient use of and satisfaction with community pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication therapy management (MTM) service. Pharmacist and patient outcome measures will be collected by surveys, interviews, and review of pharmacy records.

Key facts

Study ID

NCT02937545

Run by

Duke University

People needed

190

Starts

2017-02-22

Expected to finish

2019-09-10

Last updated by the study team

2021-06-03

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Pharmacist participants must be community pharmacists licensed and practicing in North Carolina
• Patient participants must be prescribed one of the 10 eligible medications (aripiprazole, carisoprodol, celecoxib, citalopram, clopidogrel, metoprolol, nortriptyline, paroxetine, simvastatin, warfarin)
• Patient participants must be able to consent to participating and testing on their own, and be able to read English

You may not qualify if…

• Patients who have previously undergone pharmacogenetic testing will not be eligible.

Where it is running

• Duke University — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.